Table 6—

Additional characteristics of subjects included in the four clusters defined by the diana method

Cluster
1234
Subjects n111011242
Male8 (72.7)9 (90.0)68 (60.7)24 (57.1)
Macroscopic emphysema#4 (36.4)2 (20.0)3 (2.7)2 (4.8)
PEF variability5 (45.5)4 (40.0)11 (9.8)9 (21.4)
Eczema6 (54.6)2 (20.0)47 (42.0)20 (47.6)
Rhinitis8 (72.7)2 (20.0)73 (65.2)30 (71.4)
Hospitalised+ ever4 (36.4)2 (20.0)18 (16.1)9 (21.4)
Hospitalised+ in last year1 (9.1)0 (0)1 (0.9)4 (9.5)
Inhaled β2-agonist7 (63.6)3 (30.0)36 (32.1)14 (33.3)
Inhaled corticosteroids3 (27.3)2 (20.0)29 (25.9)17 (40.5)
Inhaled antimuscarinic0 (0)1 (10.0)0 (0)1 (2.4)
Any inhaler7 (63.6)4 (40.0)40 (35.7)18 (42.9)
Age yrs65.9±6.764.0±9.455.5±14.558.5±11.4
Eosinophils 109 cells·L−10.24±0.150.22±0.210.19±0.130.28±0.16
MMEF % pred24.0±8.830.9±13.765.8±24.064.4±24.8
sGaw % pred35.7±25.044.9±18.372.7±26.173.6±28.0
Maximum PEF variability§24.7±15.718.4±17.011.4±7.313.9±15.9
SGRQ score30.9±19.123.7±13.810.9±11.923.3±17.8
  • Data are presented as mean±sd or n (%), unless otherwise indicated. PEF: peak expiratory flow; MMEF: maximal mid-expiratory flow; % pred: % predicted; sGaw: specific airway conductance; SGRQ: St George’s Respiratory Questionnaire. #: radiological (computed tomography) evidence of definite emphysematous changes; : variability of >20% during 1 week of testing; +: due to respiratory disorder; §: amplitude of mean.